Retractable Technologies, Inc. — Cyborg Score 4/10
Mixed
Medical Devices - Safety Injection Devices & Syringes
Strategic Profile
The company competes in the specialized medical device segment with proprietary VanishPoint, Patient Safe, and EasyPoint branded products. As a micro-cap with significant insider ownership, leadership has demonstrated confidence through substantial share purchases, though the company faces challenges as a thinly-traded OTC equity.
Cyborg Score Rationale
While Retractable Technologies operates in a defensible niche market with specialized safety syringe technology, the company faces significant headwinds including minimal analyst coverage, micro-cap valuation under $25M, and unprofitability. The strong insider buying by CEO Thomas Shaw suggests confidence, but execution risk remains high.
Top Insights
CEO Thomas Shaw has made substantial insider purchases over recent years, accumulating over $800K worth of shares at prices between $0.60-$0.80
Company operates with near-zero analyst coverage and minimal institutional interest, creating information asymmetry
Recent approval from Australian government suggests international expansion potential in key healthcare markets
Operates in the high-growth safety medical device segment driven by needlestick injury prevention regulations
Named Competitors
Safety syringes and injection devices — Large-cap medical device manufacturer with broad safety product portfolio
Safety injection devices — Healthcare services and products distributor with safety device offerings
Specialty medical devices — Mid-cap medical device company with injection and infusion device portfolio
Recent Developments
(November 2025) CEO acquisition of 5,731 shares, continuing pattern of insider buying